New insights from the future of interventional psychiatry are highlighting an emerging opportunity to address one of the most persistent challenges in cancer survivorship. Researchers are proposing a framework for adapting transcranial magnetic stimulation (TMS) as a smoking cessation intervention specifically designed for cancer survivors.
Despite significant advances in cancer treatment, continued cigarette smoking after diagnosis remains a major concern. Ongoing tobacco use is associated with increased mortality, greater risk of recurrence, more treatment-related complications, and reduced quality of life. While many patients express a desire to quit, long-term abstinence can be difficult to achieve, particularly when smoking is intertwined with depression, anxiety, stress, pain, and other psychological challenges.
Why Smoking Cessation Remains Difficult After Cancer Treatment
Traditional smoking cessation approaches often include counseling, behavioral interventions, and medications. While these strategies can be effective, they do not work equally well for every patient.
Cancer survivors frequently face unique stressors that may complicate quit attempts. Concerns about disease recurrence, treatment side effects, chronic pain, and emotional distress can reinforce nicotine dependence. In many cases, smoking becomes linked to coping mechanisms that are difficult to replace.
As a result, researchers continue to explore treatments that can target both tobacco use and the psychological conditions that often accompany it.
A New Direction For TMS Smoking Cessation For Cancer Survivors
TMS is a noninvasive neuromodulation therapy that uses magnetic pulses to stimulate targeted brain regions. The treatment is already approved by the U.S. Food and Drug Administration for major depressive disorder and smoking cessation.
The new paper argues that TMS may be particularly well suited for cancer survivors because of its multitarget effects. Beyond reducing nicotine cravings, TMS has demonstrated benefits for conditions commonly experienced within cancer populations, including depression, anxiety symptoms, suicidal ideation, and chronic pain.
Rather than simply applying existing smoking cessation protocols, the authors propose adapting TMS delivery to better fit the realities of oncology care.
Why The Adaptation Framework Matters
One of the most important aspects of the proposal is its emphasis on stakeholder engagement.
The researchers recommend involving cancer survivors, oncology clinicians, tobacco treatment specialists, TMS providers, and healthcare administrators in the design process. This collaborative approach seeks to ensure that future treatment protocols are practical, accessible, and responsive to patient needs.
The framework also recognizes that cancer survivors often face scheduling demands that differ from those of other patient populations. Frequent medical appointments, treatment-related fatigue, transportation barriers, and fluctuating health status may all affect treatment participation.
Because of these realities, flexibility becomes a critical consideration.
Key Recommendations From The Proposed Roadmap
Several adaptation strategies are outlined in the paper.
Researchers suggest evaluating flexible dosing schedules and accelerated TMS protocols that could reduce treatment burden while maintaining therapeutic effects. They also encourage future studies to measure outcomes beyond smoking cessation alone.
For example, investigators may examine changes in depression severity, anxiety symptoms, pain levels, quality of life, and overall functioning. These broader measures could provide a more complete picture of how TMS affects survivorship outcomes.
The framework also highlights implementation planning as an early priority. Integrating TMS into oncology settings may require coordination among multiple specialties, workforce training, and strategies to improve equitable access.
Understanding The Potential Mechanisms
The rationale behind this approach is grounded in the interconnected nature of smoking behavior and mental health.
Neural circuits involved in craving, reward processing, impulse control, and emotional regulation overlap considerably. By modulating these networks, TMS may influence several factors that contribute to tobacco dependence at the same time.
This broader neurological effect distinguishes TMS from interventions that focus exclusively on nicotine replacement or behavioral modification.
What Could Come Next
Importantly, the authors are not claiming that efficacy has already been established in cancer survivors. Instead, they present a roadmap for systematic adaptation before large-scale clinical trials are conducted.
That measured approach may ultimately strengthen future research efforts. By identifying barriers early and tailoring protocols to real-world oncology settings, investigators can improve the likelihood that future studies generate meaningful and clinically relevant results.
As cancer survivorship continues to grow worldwide, innovative approaches to smoking cessation will remain a priority. TMS Smoking Cessation For Cancer Survivors represents a promising area of investigation that sits at the intersection of oncology, psychiatry, and neuromodulation. If future trials validate the proposed framework, TMS could become an important tool for improving both health outcomes and quality of life among cancer survivors seeking lasting freedom from tobacco dependence.
Citations
Rakesh G, Weber TN, Ekhtiari H, Burris JL. Transcranial Magnetic Stimulation (TMS) for Smoking Cessation in Cancer Survivors: A Path Forward. Cancer Epidemiology, Biomarkers & Prevention (2026). DOI: https://doi.org/10.1158/1055-9965.EPI-26-0075
National Cancer Institute. Smoking and Cancer. https://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco
Explore more at https://www.interventionalpsychiatry.org